文献速递胸部肿瘤支持与姑息治疗

左前降支冠状动脉放疗剂量与非小细胞肺癌患者主要不良心脏事件及死亡率的关联

Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non-Small Cell Lung Cancer.
PubMed 文献 · JAMA Oncol · 2021-01-01

这项回顾性队列分析纳入701例局部晚期非小细胞肺癌患者,评估心脏亚结构放疗剂量与主要不良心脏事件(MACE)及全因死亡率的独立关联。结果显示左前降支冠状动脉V15 Gy≥10%与MACE风险升高(调整HR 13.90;95%CI 1.23-157.21;95%CI 1.09-2.29;而左心室V15 Gy≥1%在冠心病患者中增加MACE风险(8.4% vs 4.1%;

要点

  • 左前降支V15 Gy≥10%是无冠心病患者MACE和全因死亡的独立预测因素。
  • 左心室V15 Gy≥1%在已有冠心病患者中与1年MACE风险升高相关。
  • 心脏剂量约束可能需要根据患者是否已有冠心病进行个体化制定。

研究设计与样本

  • 回顾性队列分析,纳入2003年12月1日至2014年1月27日在哈佛大学附属医院接受胸部放疗的701例局部晚期非小细胞肺癌患者。
  • 手动勾画心脏亚结构,计算放疗剂量参数(平均、最大及每5 Gy递增的受照体积百分比)。
  • 采用受试者工作特征曲线和切点分析评估MACE,并使用Fine and Gray和Cox回归调整基线冠心病及其他预后因素。

主要发现

  • 左前降支V15 Gy≥10%的C-index为0.64,左回旋支V15 Gy≥14%为0.64,左心室V15 Gy≥1%为0.64,总冠状动脉平均剂量≥7 Gy为0.62。
  • 在无冠心病患者中,左前降支V15 Gy≥10%组1年MACE发生率为4.9%,而对照组为0%。
  • 在无冠心病患者中,左回旋支V15 Gy≥14%组1年MACE发生率为5.2%,对照组为0.7%。
  • 在无冠心病患者中,左心室V15 Gy≥1%组1年MACE发生率为5.0%,对照组为0.4%。
  • 在无冠心病患者中,总冠状动脉平均剂量≥7 Gy组1年MACE发生率为4.8%,对照组为0%。

临床怎么用

  • 放疗计划设计时应关注左前降支冠状动脉V15 Gy≥10%等心脏亚结构剂量参数,尤其对无冠心病患者。
  • 对已有冠心病患者,左心室V15 Gy≥1%可能提示MACE风险升高,需加强心脏风险分层与缓解策略。
  • 心脏剂量约束可能需要根据患者基线冠心病状态个体化制定,上述切点值得进一步研究验证。

局限性

  • 本研究为回顾性队列分析,可能存在残余混杂。
  • 心脏亚结构为手动勾画,不同勾画者间可能存在差异。
  • 左前降支V15 Gy≥10%与MACE关联的95%CI较宽(1.23-157.21),提示估计不精确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Radiotherapy accelerates coronary heart disease (CHD), but the dose to critical cardiac substructures has not been systematically studied in lung cancer. OBJECTIVE: To examine independent cardiac substructure radiotherapy factors for major adverse cardiac events (MACE) and all-cause mortality in patients with locally advanced non-small cell lung cancer (NSCLC). DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort analysis of 701 patients with locally advanced NSCLC treated with thoracic radiotherapy at Harvard University-affiliated hospitals between December 1, 2003, and January 27, 2014, was performed. Data analysis was conducted between January 12, 2019, and July 22, 2020. Cardiac substructures were manually delineated. Radiotherapy dose parameters (mean, maximum, and the volume [V, percentage] receiving a specific Gray [Gy] dose in 5-Gy increments) were calculated. Receiver operating curve and cut-point analyses estimating MACE (unstable angina, heart failure hospitalization or urgent visit, myocardial infarction, coronary revascularization, and cardiac death) were performed. Fine and Gray and Cox regressions were adjusted for preexisting CHD and other prognostic factors. MAIN OUTCOMES AND MEASURES: MACE and all-cause mortality. RESULTS: Of the 701 patients included in the analysis, 356 were men (50.8%). The median age was 65 years (interquartile range, 57-73 years). The optimal cut points for substructure and radiotherapy doses (highest C-index value) were left anterior descending (LAD) coronary artery V15 Gy greater than or equal to 10% (0.64), left circumflex coronary artery V15 Gy greater than or equal to 14% (0.64), left ventricle V15 Gy greater than or equal to 1% (0.64), and mean total coronary artery dose greater than or equal to 7 Gy (0.62). Adjusting for baseline CHD status and other prognostic factors, an LAD coronary artery V15 Gy greater than or equal to 10% was associated with increased risk of MACE (adjusted hazard ratio, 13.90; 95% CI, 1.23-157.21; P = .03) and all-cause mortality (adjusted hazard ratio, 1.58; 95% CI, 1.09-2.29; P = .02). Among patients without CHD, associations with increased 1-year MACE were noted for LAD coronary artery V15 Gy greater than or equal to 10% (4.9% vs 0%), left circumflex coronary artery V15 Gy greater than or equal to 14% (5.2% vs 0.7%), left ventricle V15 Gy greater than or equal to 1% (5.0% vs 0.4%), and mean total coronary artery dose greater than or equal to 7 Gy (4.8% vs 0%) (all P ≤ .001), but only a left ventricle V15 Gy greater than or equal to 1% increased the risk among patients with CHD (8.4% vs 4.1%; P = .046). Among patients without CHD, 2-year all-cause mortality was increased with an LAD coronary artery V15 Gy greater than or equal to 10% (51.2% vs 42.2%; P = .009) and mean total coronary artery dose greater than or equal to 7 Gy (53.2% vs 40.0%; P = .01). CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that optimal cardiac dose constraints may differ based on preexisting CHD. Although the LAD coronary artery V15 Gy greater than or equal to 10% appeared to be an independent estimator of the probability of MACE and all-cause mortality, particularly in patients without CHD, left ventricle V15 Gy greater than or equal to 1% appeared to confer an increased risk of MACE among patients with CHD. These constraints are worthy of further study because there is a need for improved cardiac risk stratification and aggressive risk mitigation strategies.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Atkins KM, Chaunzwa TL, Lamba N, et al. Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non-Small Cell Lung Cancer. JAMA Oncol. 2021. PMID: 33331883. doi:10.1001/jamaoncol.2020.6332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。